Novavax Class Action: $47M Settlement Details Revealed
Unpacking the $47 Million Settlement: A Deep Dive into the Novavax Lawsuit The recent $47 million settlement in the Sinnathurai v. Novavax class action lawsuit provides a critical case study in the complexities of pharmaceutical transparency during a public health crisis. This settlement, while significant, represents a compromise avoiding a potentially far more costly and lengthy trial. The lawsuit centered on allegations that Novavax misled investors regarding its COVID-19 vaccine development, leading to potentially inflated stock prices....